{"id":111,"date":"2025-09-23T17:13:32","date_gmt":"2025-09-23T15:13:32","guid":{"rendered":"https:\/\/bicconference.org\/2017\/?page_id=111"},"modified":"2025-09-23T17:13:34","modified_gmt":"2025-09-23T15:13:34","slug":"programme-17","status":"publish","type":"page","link":"https:\/\/bicconference.org\/2017\/programme-17\/","title":{"rendered":"Programme 17"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; locked=&#8221;off&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_code admin_label=&#8221;.titoli&#8221; module_class=&#8221;titoli&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;]<pee>Programme<\/pee>[\/et_pb_code][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=&#8221;BOTTONI&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_code _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<div id=\"dayBAR\"><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><a href=\"https:\/\/bicconference.org\/2017\/programme-15\" target=\"_top\"><\/p>\n<div class=\"prDAYsmall margin05\">FRIDAY, 15th September<\/div>\n<p><\/a><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><a href=\"https:\/\/bicconference.org\/2017\/programme-16\" target=\"_top\"><!-- [et_pb_line_break_holder] --><\/p>\n<div class=\"prDAYsmall\">SATURDAY, 16th September<\/div>\n<p><\/a><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<div class=\"prDAYbig margin50\">SUNDAY, 17th September<\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<div style=\"clear: both;\"><\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/div>\n<p>[\/et_pb_code][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=&#8221;TABELLA&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_code _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<table><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSESSION\">SCIENTIFIC SESSION 7 \u2013 Side effects of replacement therapy<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Chairs: Frits R. Rosendaal, Giovanni Di Minno<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">09.00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR scientific\"><strong>Randomisation or real world data?<\/strong><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Frits R. Rosendaal, the Netherlands<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">09.30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR scientific\"><strong>Current prophylaxis regimens are delaying but not preventing onset of joint arthropathy <\/strong><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Johannes B. Oldenburg, Germany<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">10.00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR scientific\"><strong>Predictors of outcome in immune tolerance induction (ITI): the Italian Registry<\/strong><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Giovanni Di Minno, Italy<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">10.30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR scientific\"><strong>Do we need to monitor for neurological adverse events in hemophilia?<\/strong><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Michael Makris, UK<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"TRdivisori\" colspan=\"2\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">11.00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR poster\"><strong>Break &amp; Poster Session<\/strong><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"TRdivisori\" colspan=\"2\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSESSION\">ORAL COMMUNICATIONS SESSION<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">11.30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR latest\"><strong>Oral communications: Translational Science<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><\/strong><em>Chairs: Karen Vanhoorelbeke, Sebastien Lacroix-Desmazes. Embargoed until 14th Sept.<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Towards a clinically relevant hybrid adenovirus-Sleeping Beauty transposon vector for gene therapy for von Willebrand disease<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Irina Portier (Belgium)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Treatment of hemophilia A by injection of FVIII-encoding mRNA<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Jules Russick (France)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe haemophilia A<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Chiara Borsotti (Italy)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Pharmacokinetic profile of rFVIIIFc-VWF-XTEN (BIVV001) protein in <!-- [et_pb_line_break_holder] -->cynomolgus monkey generated from a large-scale manufacturing stable cell<!-- [et_pb_line_break_holder] --> line<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Joe Salas (USA)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Recombinant factor VIII Fc fusion protein exhibits immunomodulatory effects on antigen presenting cells<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Katalin Kis-Toth (USA)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Scavenger-receptor stabilin-2 is a major regulator of mouse VWF propeptide clearance<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Orla Rawley (Canada)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->An open conformation of ADAMTS13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Elien Roose (Belgium)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Profiling of anti-ADAMTS13 antibodies derived from patients with acquired thrombotic thrombocytopenic purpura<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Nuno Graca (the Netherlands)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->The role of von Willebrand factor in experimental malaria-associated acute respiratory distress syndrome<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Sirima Kraisin (Belgium)<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"TRdivisori\" colspan=\"2\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">13.00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR poster\"><strong>Lunch &amp; Poster Session<\/strong><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"TRdivisori\" colspan=\"2\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">14.00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR latest\"><strong>Oral communications: Clinical Science<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><\/strong><em>Chairs: Jenny Goudemand, Reinhard Schneppenheim. Embargoed until 14th Sept.<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Fitusiran, an investigational RNAi therapeutic targeting antithrombin <!-- [et_pb_line_break_holder] -->for the treatment of hemophilia A or B with and without inhibitors: <!-- [et_pb_line_break_holder] -->Interim results from a Phase 2 extension study<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Pratima Chowdary (UK)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->\u201cFEIBA Global Outcome study (FEIBA GO)\u201d first data read-out: Real world <!-- [et_pb_line_break_holder] -->bleeding frequency in inhibitors patients on prophylaxis with APCC<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Roberto Crea (Austria)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->A cumulative review on four decades of thrombo-embolic events reported <!-- [et_pb_line_break_holder] -->with the use of activated prothrombin complex concentrate (APCC) in <!-- [et_pb_line_break_holder] -->congenital hemophilia<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Alessandro Gringeri (Austria)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Influence of variant VWF multimer patterns on the diagnosis of VWD type 2B<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Reinhard Schneppenheim (Germany)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Comparing platelet-dependent von Willebrand factor activity assays in <!-- [et_pb_line_break_holder] -->661 patients with von Willebrand disease \u2013 from the WiN Study<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Johan Boender (the Netherlands)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Is type 3 VWD an homogeneous group?<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Jenny Goudemand (France)<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSESSION\">SCIENTIFIC SESSION 8 \u2013 Thrombotic thrombocytopenic purpura<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Chairs: Dominique Meyer, Flora Peyvandi<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">15.00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR scientific\"><strong>Emerging concepts in acquired thrombotic thrombocytopenic purpura <\/strong><em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Karen Vanhoorelbeke, Belgium<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">15.30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR scientific\"><strong>Immune recognition of ADAMTS13 in acquired thrombotic thrombocytopenic purpura (TTP) <\/strong><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Jan Voorberg, the Netherlands<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">16.00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR scientific\"><strong>Thrombotic microangiopathies<\/strong><em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Paul Coppo, France<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"TRdivisori\" colspan=\"2\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">16.30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR poster\"><strong>Break &amp; Poster Session<\/strong><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"TRdivisori\" colspan=\"2\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\"><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSESSION\">SCIENTIFIC SESSION 9 \u2013 Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Chairs: Pier Mannuccio Mannucci, Giuseppe Remuzzi<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">17.00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR scientific\"><strong>The most recent advances in <!-- [et_pb_line_break_holder] -->atypical hemolytic uremic syndrome (aHUS) and thrombotic <!-- [et_pb_line_break_holder] -->thrombocytopenic purpura (TTP) including complement and von Willebrand <!-- [et_pb_line_break_holder] -->factor (VWF) complement interactions<\/strong><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Marina Noris and Giuseppe Remuzzi, Italy<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdORARI\">17.30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdDESCR scientific\"><strong>Treatment monitoring in the atypical hemolytic uremic syndrome (HUS)<\/strong><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Massimo Cugno, Italy<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"class_list":["post-111","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/bicconference.org\/2017\/wp-json\/wp\/v2\/pages\/111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bicconference.org\/2017\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bicconference.org\/2017\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bicconference.org\/2017\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bicconference.org\/2017\/wp-json\/wp\/v2\/comments?post=111"}],"version-history":[{"count":2,"href":"https:\/\/bicconference.org\/2017\/wp-json\/wp\/v2\/pages\/111\/revisions"}],"predecessor-version":[{"id":114,"href":"https:\/\/bicconference.org\/2017\/wp-json\/wp\/v2\/pages\/111\/revisions\/114"}],"wp:attachment":[{"href":"https:\/\/bicconference.org\/2017\/wp-json\/wp\/v2\/media?parent=111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}